Rpgupta Pharmamed Profile
Key Indicators
- Authorised Capital ₹ 2.60 M
as on 30-07-2024
- Paid Up Capital ₹ 2.60 M
as on 30-07-2024
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -0.40%
(FY 2023)
- Profit -33.33%
(FY 2023)
- Ebitda
- Net Worth -0.00%
(FY 2023)
- Total Assets -0.00%
(FY 2023)
About Rpgupta Pharmamed
The Corporate was formerly known as Mangal Murti Dealtrade Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.60 M and a paid-up capital of Rs 2.60 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Tibrewal, Anup Tibrewal, Ashish Tibrewal, and One other member serve as directors at the Company.
- CIN/LLPIN
U46497WB2010PTC153665
- Company No.
153665
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rpgupta Pharmamed?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Tibrewal  | Director | 06-Oct-2010 | Current |
| Anup Tibrewal | Director | 06-Oct-2010 | Current |
| Ashish Tibrewal | Director | 06-Oct-2010 | Current |
| Gayatri Tibrewal | Additional Director | 08-Jun-2024 | Current |
Financial Performance of Rpgupta Pharmamed.
Rpgupta Pharmamed Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.4% decrease. The company also saw a substantial fall in profitability, with a 33.33% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rpgupta Pharmamed?
In 2023, Rpgupta Pharmamed had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jeen Lifesciences Private LimitedActive 6 years 8 monthsAnand Tibrewal, Anup Tibrewal and 1 more are mutual person
Gayatripharma Med Private LimitedActive 17 years 6 monthsAnand Tibrewal, Anup Tibrewal and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rpgupta Pharmamed?
Unlock and access historical data on people associated with Rpgupta Pharmamed, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rpgupta Pharmamed, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rpgupta Pharmamed's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
